Cytokinetics to Host Investor & Analyst Day on October 16, 2024
Cytokinetics (Nasdaq: CYTK) will host an Investor and Analyst Day on October 16, 2024, from 8:30 AM to 11:30 AM ET at the Nasdaq MarketSite in New York City. The event, titled 'Heart Forward: Advancing Cardiac Myosin Modulation,' will be streamed live online.
The company's leadership and expert clinicians will discuss cardiac myosin modulation programs and opportunities in specialty care cardiovascular markets. A key focus will be the global commercial launch preparations for aficamten, a cardiac myosin inhibitor being developed for obstructive hypertrophic cardiomyopathy (HCM).
Featured expert clinicians include Dr. Mariko Harper, Dr. Shepard D. Weiner, and Dr. G. Michael Felker. Interested parties must register online by October 13, 2024. The webcast replay will be available until April 16, 2025.
Cytokinetics (Nasdaq: CYTK) ospiterà una Giornata per Investitori e Analisti il 16 ottobre 2024, dalle 8:30 alle 11:30 ET presso il Nasdaq MarketSite a New York City. L'evento, intitolato 'Heart Forward: Avanzando nella Modulazione della Miosina Cardica,' sarà trasmesso in live streaming online.
Il team dirigente dell'azienda e clinici esperti discuteranno dei programmi di modulazione della miosina cardiaca e delle opportunità nei mercati cardiovascolari di cura specialistica. Un focus principale saranno i preparativi per il lancio commerciale globale di aficamten, un inibitore della miosina cardiaca in fase di sviluppo per l'ipertrofia cardiaca ostruttiva (HCM).
I clinici esperti presenti includono il Dr. Mariko Harper, il Dr. Shepard D. Weiner e il Dr. G. Michael Felker. Le parti interessate devono registrarsi online entro il 13 ottobre 2024. La registrazione del webcast sarà disponibile fino al 16 aprile 2025.
Cytokinetics (Nasdaq: CYTK) llevará a cabo un Día de Inversores y Analistas el 16 de octubre de 2024, de 8:30 a 11:30 AM ET en el Nasdaq MarketSite en la ciudad de Nueva York. El evento, titulado 'Heart Forward: Avanzando en la Modulación de Miosina Cardíaca,' se transmitirá en vivo por internet.
El liderazgo de la compañía y clínicos expertos discutirán los programas de modulación de miosina cardíaca y oportunidades en los mercados cardiovasculares de atención especializada. Un enfoque clave será la preparación para el lanzamiento comercial global de aficamten, un inhibidor de miosina cardíaca que se está desarrollando para la miocardiopatía hipertrófica obstructiva (HCM).
Los clínicos expertos que participarán incluyen al Dr. Mariko Harper, al Dr. Shepard D. Weiner y al Dr. G. Michael Felker. Las partes interesadas deben registrarse en línea antes del 13 de octubre de 2024. La repetición de la transmisión estará disponible hasta el 16 de abril de 2025.
Cytokinetics (Nasdaq: CYTK)는 2024년 10월 16일 오전 8시 30분부터 오후 11시 30분 ET까지 뉴욕시 Nasdaq MarketSite에서 투자자 및 애널리스트의 날을 개최합니다. 이 행사는 'Heart Forward: 심장 미오신 조절 발전하기'라는 제목으로 온라인 생중계될 예정입니다.
회사의 리더십과 전문 임상의들은 심장 미오신 조절 프로그램과 전문 치료 심혈관 시장에서의 기회에 대해 논의할 것입니다. 주요 초점은 비후성 심근병증 (HCM)을 위해 개발 중인 심장 미오신 억제제인 aficamten의 전세계 상업 출시 준비입니다.
참여하는 전문 임상의는 Dr. Mariko Harper, Dr. Shepard D. Weiner, Dr. G. Michael Felker입니다. 관심 있는 당사자는 2024년 10월 13일까지 온라인으로 등록해야 합니다. 웹캐스트 재생은 2025년 4월 16일까지 이용 가능합니다.
Cytokinetics (Nasdaq: CYTK) organisera une Journée des Investisseurs et des Analystes le 16 octobre 2024, de 8h30 à 11h30 ET au Nasdaq MarketSite à New York. Cet événement, intitulé 'Heart Forward: Avancer dans la Modulation de la Miosine Cardiaque,' sera diffusé en direct en ligne.
La direction de l'entreprise et des cliniciens experts discuteront des programmes de modulation de la miosine cardiaque et des opportunités dans les marchés cardiovasculaires de soins spécialisés. Un point clé sera les préparatifs de lancement commercial mondial pour aficamten, un inhibiteur de la miosine cardiaque en développement pour la cardiomyopathie hypertrophique obstructive (HCM).
Les cliniciens experts invités incluent Dr. Mariko Harper, Dr. Shepard D. Weiner et Dr. G. Michael Felker. Les parties intéressées doivent s'inscrire en ligne avant le 13 octobre 2024. La rediffusion du webinaire sera disponible jusqu'au 16 avril 2025.
Cytokinetics (Nasdaq: CYTK) veranstaltet am 16. Oktober 2024 von 8:30 bis 11:30 Uhr ET einen Investor- und Analystentag im Nasdaq MarketSite in New York City. Die Veranstaltung mit dem Titel 'Heart Forward: Fortschritte in der Modulation der Herzmyosine' wird live online gestreamt.
Die Unternehmensleitung und Fachärzte werden die Programme zur Modulation der Herzmyosine sowie Chancen im Bereich der spezialisierten kardiovaskulären Versorgung diskutieren. Ein zentraler Punkt wird die globale Markteinführungsvorbereitung für aficamten sein, einen Herzmyosinhemmer, der zur Behandlung der obstruktiven hypertrophen Kardiomyopathie (HCM) entwickelt wird.
Zu den präsentierenden Fachärzten gehören Dr. Mariko Harper, Dr. Shepard D. Weiner und Dr. G. Michael Felker. Interessierte Parteien müssen sich bis zum 13. Oktober 2024 online registrieren. Die Aufzeichnung des Webcasts wird bis zum 16. April 2025 verfügbar sein.
- None.
- None.
Company Leadership to Discuss Cardiac Myosin Modulation, Specialty Cardiology Programs and Commercial Launch Preparations
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host an Investor and Analyst Day on Wednesday, October 16, 2024 from 8:30 AM to 11:30 AM ET. The event, entitled “Heart Forward: Advancing Cardiac Myosin Modulation,” will be held at the Nasdaq MarketSite in New York City, and streamed live online.
Members of Cytokinetics’ senior leadership team will be joined by expert clinicians to discuss the Company’s cardiac myosin modulation programs and opportunities to address high unmet clinical needs in specialty care cardiovascular markets. Included amongst these topics will be discussion and elaboration on the global commercial launch preparations for aficamten, a next-in-class cardiac myosin inhibitor in development for the potential treatment of patients with obstructive hypertrophic cardiomyopathy (HCM).
The event will feature the following expert clinicians:
- Mariko Harper, M.D., MS, FACC, Medical Director, The Hypertrophic Cardiomyopathy Center, Virginia Mason Franciscan Health
- Shepard D. Weiner, M.D., Medical Director, Hypertrophic Cardiomyopathy Center and Associate and Professor of Medicine, Columbia University Medical Center
- G. Michael Felker, M.D., MHS, FACC, FAHA, FHFSA, Professor of Medicine, Division of Cardiology, Duke Clinical Research Institute, Principal Investigator of the Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil
Interested parties must register online at https://cytokinetics-2024-analyst-and-investor-day.open-exchange.net/ by October 13, 2024. Registered attendees may access the live virtual event platform by visiting the Investor & Media section of the Cytokinetics website at www.cytokinetics.com. A link to the webcast replay will be archived on the Cytokinetics website until April 16, 2025.
About Cytokinetics
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy which were published in the New England Journal of Medicine. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
When is Cytokinetics (CYTK) hosting its Investor & Analyst Day in 2024?
What is the main focus of Cytokinetics' (CYTK) Investor & Analyst Day 2024?
Who are the expert clinicians featured at Cytokinetics' (CYTK) Investor & Analyst Day 2024?
What is aficamten being developed for by Cytokinetics (CYTK)?
How can interested parties attend Cytokinetics' (CYTK) Investor & Analyst Day 2024?
